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Abstract
Background
South Africa has a high burden of MDR-TB, and to provide accessible treatment the govern-
ment has introduced different models of care. We report the most cost-effective model after
comparing cost per patient successfully treated across 5 models of care: centralized hospital,
district hospitals (2), and community-based care through clinics or mobile injection teams.
Methods
In an observational study five cohorts were followed prospectively. The cost analysis adopted
a provider perspective and economic cost per patient successfully treated was calculated
based on country protocols and length of treatment per patient per model of care. Logistic
regression was used to calculate propensity score weights, to compare pairs of treatment
groups, whilst adjusting for baseline imbalances between groups. Propensity score weighted
costs and treatment success rates were used in the ICER analysis. Sensitivity analysis
focused on varying treatment success and length of hospitalization within each model.
Results
In 1,038 MDR-TB patients 75% were HIV-infected and 56% were successfully treated. The
cost per successfully treated patient was 3 to 4.5 times lower in the community-based mod-
els with no hospitalization. Overall, the Mobile model was the most cost-effective.
Conclusion
Reducing the length of hospitalization and following community-based models of care
improves the affordability of MDR-TB treatment without compromising its effectiveness.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB), defined as TB resistant to isoniazid and rifampi-
cin, threatens global TB control [1]. Although MDR-TB represents only 7% of incident TB in
South Africa, high drug prices, lengthy treatment and hospitalization lead to exorbitant costs,
and in 2014, approximately 65% of the National Tuberculosis Program budget was spent on
MDR-TB control [1–3].
A number of global studies, including two systematic reviews, have reported higher costs
associated with managing MDR-TB patients in hospital [2, 4–7]. Although a number of studies
recommend community-based models of treatment and limiting hospitalization, few compare
models of care in large cohorts without having to rely on some hypothetical implementation.
The province of KwaZulu-Natal has amongst the highest prevalence of patients with
MDR-TB in South Africa [8]. Until 2008, local management of MDR-TB required hospitaliza-
tion in a centralized specialized hospital, but the rising caseload rendered this model of care
impractical. In 2008, new models of care were implemented in certain areas of the province
(Table 1): decentralized care (rural district hospitals with non-specialist doctors providing hos-
pitalization and care), and community-based care (patients were not hospitalized, but treated in
their homes by a mobile injection team or at the nearest clinic). In other areas, the existing cen-
tralized model of care (specialized referral center providing hospitalization and subsequent
care), remained in place. Decentralized and community-based models of care were introduced
to increase accessibility of MDR-TB services, reduce the duration of hospitalization and enable
all patients to commence treatment immediately without waiting for a hospital bed. Monitoring
was poor, and therefore, interpretation and implementation of the new models of care varied
[9]. Health care workers anxious about MDR-TB transmission in the community hospitalized
patients for longer than necessary [10], and, despite of a list of criteria detailing which patients
could receive community-based treatment, hospitalized most patients (S1 Table) [11].
In a previous study we evaluated the effectiveness of the new program in decentralized hos-
pitals, reporting that MDR-TB patients were more likely to have a successful treatment out-
come if they received decentralized care, compared to traditional care at a central specialized
hospital (adjusted OR = 143, p = 001) [10]. The cost-effectiveness of the various models,
Table 1. Models of care for MDR-TB patients in KwaZulu-Natal 2009–2012.
Models of Care Level of care Length of hospitalization MDR-TB Clinic Visits Mobile Visits
OPD† Visits
Centralized
hospital
Specialized
Hospital
Initial hospitalization for all
patients
Monthly MDR-TB OPD visits at
centralized hospital after discharge
as an inpatient
If patient discharged during
intensive phase received injectable at
local clinic.
Not applicable
Decentralized 2 District
Hospital
Hospitalization for all
patients for whole injectable
phase
After discharge monthly OPD visits Not applicable Not applicable
Decentralized 1 District
Hospital
Initial hospitalization for all
patients
After discharge monthly OPD visits If patient discharged during
intensive phase received injectable
from local clinic or a mobile.
Not applicable
Community-
based
Clinic No hospitalization for any
patient
Monthly at decentralized Hospital During intensive phase received
injectable from local clinic.
Not applicable
Community-
based
Mobile No hospitalization for any
patient
Monthly at decentralized Hospital Not applicable During intensive phase
received injectable from
mobile.
 MDR-TB: Multidrug-resistant TB, TB resistant to isoniazid and rifampicin;
† OPD: Outpatient department
https://doi.org/10.1371/journal.pone.0196003.t001
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however, was still unknown. Given the size of the MDR-TB epidemic and the cost of treat-
ment, determining cost-effectiveness is critical for policy makers and TB program managers.
In this study, we defined cost-effectiveness as provider costs per successfully treated patient.
We then addressed the following question: which model of care is most cost-effective?
Methods
Study population: Patients and health facilities
In our prospective cohort study, all MDR-TB patients 18 years who started treatment
between July 2008 and July 2010 were enrolled. Patients were excluded if they had additional
resistance to a fluoroquinolone or a second-line injectable agent (i.e., pre-extensively drug-
resistant TB [pre-XDR TB]) or both (XDR TB). All patients who lived within the catchment
area of the decentralized site were enrolled at that site if they met the study criteria. At the cen-
tralized hospital, all patients who met the study criteria were enrolled, unless they came from
the catchment areas of a decentralized site.
MDR-TB patients were treated in one of the 5 models of care available at the time (Table 1).
Most patients at the centralized and decentralized sites were initially hospitalized. However, at
all three hospitals there were a few patients who met the criteria for community-based treat-
ment (S1 Table) and were not hospitalized, receiving all their treatment from their closest
clinic or a mobile injection team. We grouped all patients from the 3 hospitals who were not
hospitalized into a community-based model (clinic or mobile). The remaining patients were
assigned to the hospital to which they initially presented, were hospitalized and subsequently
managed. The new models of care were geographically positioned throughout the province,
with a strategic focus on areas with the highest incidence of MDR-TB [12]. Infrastructure and
the socio-economic profile of the populations in these areas was similar [13] (S1 Appendix).
Four decentralized sites started treating patients with MDR-TB in 2008. As their performance
varied considerably [10], for our cost-effectiveness study, we included only the best and worst
performing of these hospitals to account for the range of variability.
Data collection
We collected patient data from medical notes and the MDR-TB treatment register. For each
patient, we collected duration of treatment and hospitalization, length of intensive and contin-
uation phases, as well as HIV status and receipt of antiretroviral therapy (ART).
Using a provider perspective, we collected costs to the health service only, excluding house-
hold costs. For the hospitals, we collected recurrent costs data, broken down by category (clini-
cal staff, drugs, laboratory tests, catering and laundry) and indirect service costs (non-clinical
staff and overheads). From the MDR-TB ward and MDR-TB outpatient department (OPD),
we collected the number of Full-Time Equivalents (FTEs) per category of staff. We collected
similar financial information for the clinics and mobile injection teams. For the mobile teams
we included the capital cost of the vehicles. Financial data were extracted from the KwaZulu-
Natal provincial department of health accounts (2012).
Diagnostic and treatments costs included baseline diagnostic costs, medication required
during the 6-month intensive phase and 18-month continuation phase, ART for HIV co-
infected patients and the costs of routine monitoring at each monthly check-up. Unit costs of
laboratory tests were extracted from the National Health Laboratory Service (NHLS), state
pricing list (2012–13). Costs of chest x-rays and audiograms were obtained from the hospitals’
financial data. Drug costs were extracted from the KwaZulu-Natal central medical depot pric-
ing list (2012–13). Inpatient day (IPD) costs were calculated primarily from three categories of
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expenditure: clinical staff, direct service costs (laundry, catering), and indirect service costs.
OPD costs were derived from direct personnel costs and indirect service costs.
Activity data by facility were provided by the KwaZulu-Natal provincial department. Data
on number and type of contacts made by mobile teams were extracted from their registers.
Study outcomes
Treatment outcomes of patients were determined at the end of treatment, according to defini-
tions developed by the WHO (S2 Table) [14, 15]. Treatment success was defined as the propor-
tion of patients who were cured or completed treatment.
The primary outcomes of this study were cost-effectiveness and incremental cost-effective-
ness ratios (ICER). We defined cost-effectiveness as provider costs per successfully treated
patient compared to a no treatment option and present this cost for each model of care. ICERs
were used to compare the cost-effectiveness of the different models of treatment [16].
Data analysis
We initially had 1269 patients in our study, but excluded 231 patients at the Centralized hospi-
tal who had missing data on hospital duration. The remaining 1038 patients were included in
the cost-effectiveness analysis.
We calculated the economic costs for each patient using several steps. Firstly, we deter-
mined the type and number of contacts with the health service: numbers of IPDs, OPD visits,
number of days in the intensive phase to determine the number of injections administered
and number of days in the continuation phase to determine the number of OPD visits for
monthly monitoring.
We calculated the unit cost per type of health service contact: IPD, OPD visit, injection in
clinics or at home with mobiles, from which we quantified the cost for each patient. The cost
per patient for drugs, diagnostics and monitoring tests (laboratory, audiology and chest x-
rays) was calculated according to standard treatment protocols. We added, where relevant, the
cost of HIV related services: HIV testing, CD4 cell count and viral load tests as well as ART
associated costs. Cost of pregnancy tests for all women aged 15 to 49 were included.
For the hospitals, we obtained clinical staff cost per IPD and OPD visit, by applying the
mid-point salary package to the Full-Time Equivalents (FTEs) per category of staff [17]. This
was then divided by the total number of IPDs or OPD visits for the year. Catering, laundry and
indirect costs were calculated using each hospital’s average per IPD and OPD visit [18] (S3
Table).
We calculated recurrent cost per injection at clinics using the average cost per consultation
at the clinic. For mobiles, the cost of home injections was the sum of the annualized mobile
capital and running costs, the cost of the nurse running each mobile, with an additional 10%
overheads for planning and management. These costs were apportioned by applying the pro-
portion of MDR-TB injection visits. Capital costs were annualised over 5 years using a 3% dis-
count rate. For each patient the cost of diagnosis and treatment was calculated as follows:
Cost of Tests and Drugs + (Cost clinical staff per IPD + Other costs per IPD)  number of
IPDs + (Cost clinical staff per OPD + Other costs per OPD)  number of OPD visits + Cost
per clinic injection  number of clinics injections OR Cost per mobile injection  number of
mobiles injections.
Data collected in 2012 ZAR (the last year of our study) were inflated to 2014 using the
South African medical consumer price index of 63 for 2012 and 64 for 2013 [19]. This was
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converted to US dollars using the 2014 average annual exchange rate of USD1 = South African
rand (ZAR) 1044 [20].
Baseline characteristics and treatment outcomes were described using simple frequencies.
Where appropriate Chi-square and Fisher’s exact test, were used to test the relationship between
categorical characteristics and model of care. All baseline factors indicative of an imbalance in
treatment groups were further analysed for their individual effects on cost and effectiveness
(treatment success), respectively.
The propensity score is a balancing tool to reduce differences in the distribution of baseline
variables between treatment groups [21]. Due to the limited sample size in the mobile and
clinic models, propensity score weighting presented a more feasible approach than propensity
score matching which may result in the exclusion of patients. We created, using the variables
previous TB treatment, HIV and ART status, baseline weight and positive smear microscopy
in logistic regression, separate propensity scores to compare the following pairs of treatment
groups: Centralised vs Decentralised 2, Clinic vs Decentralised 2, Mobile vs Clinic, Decentra-
lised 1 vs Mobile. These four comparisons were ordered, according to effectiveness, from
lowest to highest for the purpose of the ICER analysis. Using the overidentification test, the
balance of covariates between treatment models was assessed and, having adjusted for the pro-
pensity score weights, the standardized differences of covariates were compared. All individu-
als with missing data for any of the covariates were excluded for this weighting exercise (S2
Appendix).
In the ICER analysis only propensity weighted costs and treatment success rates are pre-
sented. Having ordered the models of care by success rates (lowest to highest), each model was
compared to the previous model to determine which model was most cost-effective, i.e. had
the lowest provider cost per successfully treated patient. Two sensitivity analyses were con-
ducted to determine at which success rate and what number of days of hospitalization the hos-
pitalized models would become as cost-effective as the most cost-effective model.
Ethics approval
The study protocol was approved by the University of KwaZulu-Natal Biomedical Research
Ethics Committee and the KwaZulu-Natal Department of Health. Informed consent was
waived by the ethics committee, as all data had been previously collected during routine medi-
cal care and did not pose any additional risks to patients.
Results
Patient characteristics and treatment outcomes
Of the 1038 MDR-TB patients studied 52% were female and the median age was 35 years [IQR
27–43] (Table 2). HIV co-infection rates varied across the different models of care, from 84%
at Decentralized 2 to 62% in the Mobile model (p = 0.002). The proportion of HIV-infected
patients receiving ART across the modes of care varied, with 77% of patients at Decentralized
2 receiving ART compared to 100% in the Clinic and Mobile models (p<0.001). (Receipt of
ART was a criterion for admission to the community-based models for patients co-infected
with HIV). In our study cohort 114/748 (15%) of HIV-infected patients were not on ART
(Table 3). There was variation in other baseline variables across the models of care, but only
the differences in pre-treatment weight (p<0.001) and previous episodes of TB (p<0.001)
were significant. As HIV and ART status had a significant effect on treatment outcomes, we
stratified treatment outcomes by HIV and ART status (Table 3). As expected, patients co-inf-
ected with HIV not on ART had poorer treatment outcomes than those who were on ART.
Cost-effectiveness of MDR-TB treatment models
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Treatment details and costing
Duration of treatment, length of intensive phase, and length of hospitalization varied between
patients, affecting the number of injections administered to outpatients and the number of
OPD visits (Table 4). In Table 5, the mean cost per patient per type of activity and per model
are shown.
The total cost per patient treated varied significantly across the models of care (Decentral-
ized hospital 30,185USD, Decentralized 2 28, 246USD, Decentralized 1 19, 484USD, Mobile
9,394USD and Clinic 6,739USD; p<0.0001), with the average cost per patient 3 to 4.5 times
lower in the community-based models of care. Inpatient care (excluding drugs and labs) was
the main cost driver in the hospital-based models, accounting for 85% of cost per patient
treated at Decentralized 2, 84% at the Centralized hospital and 65% at Decentralized 1. In con-
trast, in the community-based models of care, tests and drugs accounted for 41% and 48% of
the costs in Mobile and Clinic care respectively. The length of hospitalization accounted for
the difference in the cost per patient treated at the two decentralised models. At Decentralized
2 the mean number of inpatient days was twice that of Decentralized 1 (158 vs 79 days)
(Table 4), with an IPD cost per patient almost twice that of Decentralized 1 (USD24,130 vs
USD12,631) (Table 5).
Having ranked the models of care from lowest to highest treatment success, the following
comparisons were used for the ICER analysis: Centralized vs Decentralized 2, Decentralized 2
versus the Clinic model, the Clinic versus the Mobile model and finally the Mobile versus
Decentralized 1. After applying propensity score weights for each of the aforementioned com-
parisons separately, previous TB, HIV and ART status, baseline weight and positive smear
microscopy were similar between the models of care. (The standardized differences between
covariates before and after weighting as well as the p-values for covariate balance are presented
in S2 Appendix.)
Propensity score weighted costs and treatment success rates are presented in Table 6. The
Centralized model of care was the least cost-effective owing to the lowest success rate and the
highest cost per patient. This was followed by Decentralized 2. The community-based models
(Clinic and Mobile) were more cost-effective than models which included hospitalisation.
Although the Mobile model was more costly than the Clinic model, it was 8% more effective,
Table 2. Baseline demographic and clinical characteristics of MDR-TB patients (N = 1038).
Patient characteristics Centralized hospital Decentralized models Community-based models
1 2 Clinic Mobile p-value
N = 582 N = 125 N = 261 N = 25 N = 45
Female 299 (51) 68 (54) 136 (52) 13 (52) 23 (51) 0.88
Median age (years, IQR) 34 (27–41) 36 (28–42) 36 (29–44) 34 (29–42) 33 (28–42) 0.3270
Median weight (kg, IQR) 53 (46–60) 49 (43–56) 52 (44–59) 48 (41–52) 52 (47–59) 0.0002
Previous TB 558 (96) 87 (70) 107 (41) 18 (72) 26/45 (58) <0.001
HIV-infected, n/total tested 411/564 (73) 96/124 (77) 197/235 (84) 16/24 (67) 28/45 (62) 0.002
On ART, n/known ART status† 331/404 (82) 92/95 (97) 129/167 (77) 16/16 (100) 28/28 (100) <0.001
Smear positive at diagnosis 406 (52) 80 (64) 195 (75) 16(64) 25(56) <0.001
Resistant to 3 drugs at baseline 470 (58) 72(58) 138(53) 15(60) 24 (53) 0.677
Data are number (%) unless otherwise stated.
 Unknown HIV status documented in: 18 patients in the centralized hospital; 1 patient in Decentralized 1; 26 patients in Decentralized 2; l patient in the Clinic and 0
patients in the Mobile models.
† Unknown ART status documented in: 7 patients in the centralized site, 1 patient at Decentralized 1 and 30 patients Decentralized 2.
https://doi.org/10.1371/journal.pone.0196003.t002
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so that overall, the Mobile model was the most cost-effective model. Although Decentralized 1
had a 1% higher success rate than the Mobile model it was substantially more expensive than
the Mobile.
Having identified treatment success and length of hospitalization as the two variables with
the greatest impact on cost per patient successfully treated, we adjusted these two variables to
assess their impact on cost-effectiveness of the models. Even if treatment success was increased
to 100% in the Centralized and Decentralized models, they remained significantly more expen-
sive than the community-based models. If the days of hospitalization at the Centralized
Table 3. Treatment outcomes of patients with MDR-TB in KwaZulu-Natal, South Africa (N = 1038).
Cured Completed treatment Treatment success† Died Failed Defaulted Transferred out
Centralized hospital (n = 582)
Total 198 (34%) 117 (20%) 315 (54%) 101 (17%) 19 (3%) 145 (25%) 2
HIV-negative 55 (36%) 34 (22%) 89 (58%) 20 (13%) 3 (2%) 41 (27%) 0
HIV-positive + ART 116 (35%) 71 (22%) 187 (57%) 57 (17%) 12 (4%) 73 (22%) 2 (0.6%)
HIV-positive no ART 17 (23%) 10 (14%) 27 (37%) 16 (22%) 4 (5%) 26 (36%) 0
Unknown HIV status 7 (39%) 2 (11%) 9 (50%) 6 (33%) 0 3 (17%) 0
HIV-positive, unknown ART status 3 (43%) 0 3 (43%) 2 (29%) 0 2 (29%) 0
Decentralized 1 (n = 125)
Total 78 (62%) 12 (10%) 90 (72%) 17 (14%) 7 (6%) 9 (7%) 2 (2%)
HIV-negative 17 (61%) 3 (11%) 20 (72%) 2 (7%) 2 (7%) 3 (11%) 1 (4%)
HIV-positive + ART 58 (63%) 9 (10%) 67 (73%) 14 (15%) 5 (5%) 5 (5%) 1 (1%)
HIV-positive no ART 2 (67%) 0 2 (67%) 0 0 1 (33%) 0
Unknown HIV status 1 (100%) 0 1 (100%) 0 0 0 0
HIV-positive, unknown ART status 0 0 0 1 (100%) 0 0 0
Decentralized 2 (n = 261)
Total 120 (46%) 15 (6%) 135 (52%) 69 (26%) 19 (7%) 28 (11%) 10 (4%)
HIV-negative 18 (47%) 2 (5%) 20 (52%) 6 (16%) 3 (8%) 8 (21%) 1 (3%)
HIV-positive + ART 72 (56%) 8 (6%) 80 (62%) 24 (19%) 10 (8%) 12 (9%) 3 (2%)
HIV-positive no ART 16 (42%) 2 (5%) 18 (47%) 11 (29%) 2 (5%) 4 (11%) 3 (8%)
Unknown HIV status 4 (15%) 2 (8%) 6 (23%) 13 (50%) 3 (12%) 2 (8%) 2 (8%)
HIV-positive, unknown ART status 10 (33%) 1 (3%) 11 (37%) 15 (50%) 1 (3%) 2 (7%) 1 (3%)
Clinic (n = 25)
Total 12 (48%) 3 (12%) 15 (60%) 4 (16%) 2 (8%) 4 (16%) 0
HIV-negative 0 1 (12%) 1 (12%) 4 (50%)¥ 2 (25%) 1 (4%) 0
HIV-positive + ART 12 (75%) 2 (12%) 14 (87%) 0 0 2 (8%) 0
HIV-positive no ART 0 0 0 0 0 0 0
Unknown HIV status 0 0 0 0 0 1 (100%) 0
HIV-positive, unknown ART status 0 0 0 0 0 0 0
Mobile (n = 45)
Total 30 (67%) 0 30 (67%) 4 (9%) 3 (7%) 5 (11%) 3
HIV-negative 6 (35%) 0 6 (35%) 4 (23%) 3 (18%) 3 (18%) 1 (6%)
HIV-positive + ART 24 (86%) 0 24 (86%) 0 0 2 (7%) 2 (7%)
HIV-positive no ART 0 0 0 0 0 0 0
Unknown HIV status 0 0 0 0 0 0 0
HIV-positive, unknown ART status 0 0 0 0 0 0 0
† Treatment success: Sum of the patients cured and completed treatment.
¥ Two patients died due to trauma, deaths not related to TB.
https://doi.org/10.1371/journal.pone.0196003.t003
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hospital was reduced to 2, the cost per successfully patient treated was still higher than that of
the community-based models. For Decentralized 1 and 2, the days of hospitalization had to be
reduced from 79 to 5 days and 158 to 6 days respectively for the cost for each successfully
treated patient to be equivalent to that of the community-based models.
Discussion
Our large study, involving 1,038 MDR-TB patients, shows that community-based care is more
cost-effective than care in either a decentralized or centralized setting as evidenced by the
lower cost per patient successfully treated in the community-based models of care. Overall, the
Mobile model was the most cost-effective model. Our findings support the recent WHO rec-
ommendation, together with that of others, for ambulatory care as the preferable model of
care for patients with MDR-TB [22–24].
Our study compared the cost-effectiveness of 5 different models of care in South Africa based
on actual implementation and individual patient data. Four other South African studies have
attempted to cost models of care, but relied on some estimated data, hypothetical implementation
or data from one program only [6, 7, 25, 26]. The costs we recorded are higher than those reported
in these studies, probably due to longer treatment durations and higher HIV co-infection rates.
Table 4. Days of treatment and numbers of attendances of MDR-TB patients (N = 1038).
Centralized Decentralized models Community-based models
hospital 1 2 Clinic Mobile
Duration of MDR-TB treatment (days) 482/595 583/719 499/664 474/687 575/693
Intensive phase
Duration (days) 187/196 177/195 167/182 164/189 179/192
Inpatient days 130/136 79/70 158/174 0 0
Injections administered in the community (days) 57/60 98/125 9/8 164/189 179/192
Number hospital OPD† visits 13/3 4/4 1/1 6.1/7 6.5/7
Number clinic injections 42/36 36/39 7/0 117/135 0
Number mobile injections 0 35/39 0 0 127/137
Continuation phase
Duration (days) 311/392 405/504 342/484 309/462 396/495
Number OPD Visits 9/12 14/17 11/16 10/15 13/16
Data are mean/median
 MDR-TB: Multidrug-resistant TB, TB resistant to isoniazid and rifampicin;
† Outpatient department
https://doi.org/10.1371/journal.pone.0196003.t004
Table 5. Cost per MDR-TB patient treated for each care model in 2014 US dollars (USD) (N = 1038).
Centralized Decentralized models Community-based models
hospital 1 2 Clinic Mobile
IPD Cost (USD) 25,282 12,631 24,130 0 0
OPD Cost (USD) 1,071 1,879 1,086 1,727 2,071
Clinic/Mobile (USD) 636 1,059 116 1,758 3,447
Tests† (USD) 1,256 1,545 1,097 1,293 1,534
Drugs (USD) 1,940 2,371 2,013 1,961 2,342
Total cost (USD) 30,185 19,484 28,246 6,739 9,394
Mean costs;
†Tests: diagnostic and monitoring tests—laboratory, audiology and chest x-rays
https://doi.org/10.1371/journal.pone.0196003.t005
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In our study, in the models of care in which patients were hospitalized (centralized and
decentralized), hospitalization was a major cost driver, accounting for 65–85% of treatment
costs. Even after controlling for duration of treatment, the cost per patient was significantly
lower in the community-based models than the models which included hospitalization. In our
setting, however, there will always be patients who require hospitalization. A number of global
studies support these findings. In a systematic review inpatient care was estimated to cost 1.6
times more than community-based care [27]. Fitzpatrick et al report that community-based
care incurred lower costs than inpatient care and was more cost-effective [2]. They recom-
mend community-based care unless there is strong evidence for hospitalization. A study in
Estonia and Russia found that hospitalization costs accounted for 67–82% of their total treat-
ment costs [5], a finding very similar to our study.
In the community-based models of care in our study—in which patients were not hospital-
ized—tests and drugs were a major cost driver, accounting for 41% of the cost of mobile ser-
vices and 48% of the cost of clinic services. The costs we report for tests and drugs are similar
to those reported by one of the South African studies [25]. We report higher costs for tests and
drugs than Sinanovic et al, which is probably due to longer treatment durations and higher
HIV co-infection rates [26].
Patient enrolment in the study started in 2008 and limited access to ART at that time acc-
ounts for the 15% of HIV-infected patients who were not on ART. ART is now more easily
accessible as eligibility criteria have changed and nurses trained to initiate ART. Furthermore,
with the introduction of the new test and treat approach in South Africa, there will soon be
very few HIV-positive patients not on ART. In patients co-infected with HIV, ART is a signifi-
cant determinant of treatment success [28, 29], and in our study 67 (59%) of HIV-positive
patients not on ART has an unsuccessful treatment outcome.
Surprisingly, the community-based models of treatment were not more effective for HIV-
negative patients. This, however, may be a consequence of the small number of HIV-negative
patients in our cohort and that 2 of the 4 deaths (out of 8 total HIV-negative patients in the
clinic model), were unrelated to MDR-TB (Table 3).
The differences between the two decentralised models highlight that alternate models of
care are not always more effective or more cost-effective. Treatment success was lower at
Decentralized 2 (Table 3). And, although decentralization aimed to reduce the length of hospi-
talization, Decentralized 2 reported long periods of hospitalization (a mean of 158 days) as
Table 6. Cost-effectiveness of the 5 models of care in 2014 US dollars (USD) using propensity score weighted costs and treatment success rate.
Model of care Success
rate
Cost per
patient (USD)
Average cost per
success (USD)
ICER
(USD)
Interpretation
Centralized 59% 30575 51822 -179 Decentralized 2 is more cost-effective than the Centralized model.
Decentralized 2 63% 29858 47394
Decentralized 2 58% 29200 50345 -2738 The Clinic model is more cost-effective than Decentralized 2.
Clinic 66% 7297 11056
Clinic 60% 6626 13943 402 The Mobile model is more effective but more costly than the Clinic model. The 8%
difference in treatment success justifies the increased cost of the mobile model.Mobile 68% 9841 11043
Mobile 72% 9957 13829 9687 Decentralized 1 is more costy than the Mobile model. The 1% difference in treatment
success does not justify the increased cost of Decentralized 1.Decentralized 1 73% 19644 26910
Final interpretation: From this analysis, the Mobile model is overall the most cost-effective model.
 Note: The four comparisons (Decentralized vs Decentralized 2, Decentralized 2 vs Clinic, Clinic vs Mobile and Mobile vs Decentralized 1) were considered separately
in propensity score analysis to match patients on their demographic and health baseline factors
https://doi.org/10.1371/journal.pone.0196003.t006
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clinicians, unconfident about managing MDR-TB and anxious about MDR-TB transmission
in the community, hospitalised patients for longer than necessary or stipulated in the guide-
lines. These findings highlight the need for regular monitoring and support during service
expansion to ensure staff understand new programs and implementation is according to
guidelines. Numerous studies have reported the difficulties in introducing and expanding new
diagnostics, algorithms or models of care [30, 31].
Community-based treatment together with decreasing the length of hospitalization reduces
provider costs of MDR-TB services. However, as we did not capture household costs, we were
unable to determine which model of care was most cost-effective to patients and society overall.
Although the diagnosis and treatment of MDR-TB in South Africa is free, patients incur sub-
stantial costs accessing health services, with the poorest patients incurring the highest costs [32,
33]. In some instances, when patients can continue with their household duties and return to
work when they respond to treatment, community-based treatment will reduce household
costs. In other instances, however, significant household costs may be incurred accessing the
clinic daily or nursing an ill patient at home. As patients with TB are poorer than the average
South African [34] and social protection against the cost of illness is a key objective of the post-
2015 Global TB strategy [35], to optimize the chance of treatment success [36] and reduce cata-
strophic costs, the mechanism for delivery of all MDR-TB services must minimise productivity
loss and provide timely social protection. In promoting community-based models of treatment,
education on infection control at a household level is essential to minimize possible transmis-
sion, the infection of a household member and additional household-level costs.
As our study reports findings from a large study cohort, of a programme implemented and
funded entirely by the Department of Health, at sites with heterogeneous treatment success,
we believe this increases the generalizability of our findings to other resource-limited settings.
This operational study evaluated an intervention implemented by the public sector, and we
had limited control over the design, scope and quality of implementation. Many patients were
excluded from our analysis due to missing data. The generalisability of our findings is limited
by the small number of patients treated in the community-based models and that there were
no HIV-infected patients not on ART in the community-based models. Additional adequately
powered studies are needed to better inform criteria for allocation to ambulatory care and to
determine which models of care are most effective in differing community contexts, as are
those investigating household costs related to MDR-TB.
We conclude that even in resource-limited settings and in the presence of HIV co-infection,
community-based care is more cost-effective than care in either a centralized or decentralized
hospital setting for patients who do not require hospitalization. As the global number of MDR-
TB patients continues to increase, our findings support the WHO call for ambulatory care.
Ambulatory care reduces the provider costs of MDR-TB treatment and possibly household
costs too. Recent advances in technology, including short course regimens, new and repurposed
drugs and mobile phones have the potential to reduce provider and household costs further. To
assess the impact of these new technologies on provider and household costs, additional cost
effectiveness studies should be performed as these interventions are implemented. However,
providing effective MDR-TB care requires a complex health system response, the complexity of
which will increase as new drugs and diagnostic tools emerge. Recognising that different models
of care are required to provide universal access to MDR-TB treatment, responsible oversight
and vigilance by National TB programs, together with appropriate investment in health systems
and staff is necessary to ensure all MDR-TB services are effective.
Cost-effectiveness of MDR-TB treatment models
PLOS ONE | https://doi.org/10.1371/journal.pone.0196003 April 18, 2018 10 / 13
Supporting information
S1 Table. Criteria for home-based treatment of MDR-TB patients.
(DOCX)
S2 Table. Treatment outcome definitions.
(DOCX)
S3 Table. Unit cost per type of activity per site.
(DOCX)
S1 Appendix. Comparison of populations included in this study.
(DOCX)
S2 Appendix. Additional methodology regarding the propensity analysis.
(DOCX)
Acknowledgments
We acknowledge the KwaZulu-Natal Department of Health and thank facility level managers,
doctors, nurses and data capturers at the study sites for their assistance. We gratefully acknowl-
edge the participants in the study.
Author Contributions
Conceptualization: Marian Loveday, Kristina Wallengren, Tarylee Reddy, Emmanuelle
Daviaud.
Data curation: Marian Loveday, Harsha Desai, Zanele Radebe, Emmanuelle Daviaud.
Formal analysis: Marian Loveday, Tarylee Reddy, Donela Besada, James C. M. Brust, Emma-
nuelle Daviaud.
Funding acquisition: Marian Loveday, Kristina Wallengren.
Investigation: Marian Loveday, Harsha Desai, Emmanuelle Daviaud.
Methodology: Marian Loveday, Kristina Wallengren, Tarylee Reddy, Donela Besada, James C.
M. Brust, Anna Voce, Zanele Radebe, Nesri Padayatchi, Emmanuelle Daviaud.
Project administration: Marian Loveday, Jacqueline Ngozo, Zanele Radebe, Iqbal Master.
Resources: Marian Loveday, Jacqueline Ngozo, Zanele Radebe, Iqbal Master, Emmanuelle
Daviaud.
Supervision: Marian Loveday, Anna Voce, Jacqueline Ngozo, Iqbal Master, Nesri Padayatchi.
Validation: Marian Loveday, Tarylee Reddy, Donela Besada, James C. M. Brust, Anna Voce,
Iqbal Master, Nesri Padayatchi, Emmanuelle Daviaud.
Visualization: Marian Loveday.
Writing – original draft: Marian Loveday, Tarylee Reddy, James C. M. Brust, Emmanuelle
Daviaud.
Writing – review & editing: Marian Loveday, Kristina Wallengren, Tarylee Reddy, Donela
Besada, James C. M. Brust, Anna Voce, Harsha Desai, Jacqueline Ngozo, Zanele Radebe,
Iqbal Master, Nesri Padayatchi, Emmanuelle Daviaud.
Cost-effectiveness of MDR-TB treatment models
PLOS ONE | https://doi.org/10.1371/journal.pone.0196003 April 18, 2018 11 / 13
References
1. World Health Organisation. Global Tuberculosis Report 2017. WHO/HTM/TB/2017.23. 2017; Geneva,
Switzerland.
2. Fitzpatrick C, Floyd K. A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multi-
drug-Resistant Tuberculosis. Pharmacoeconomics. 2012; 30(1):63–80. https://doi.org/10.2165/
11595340-000000000-00000 PMID: 22070215
3. National Health Laboratory Service. GeneXpert MTB/RIF Progress Report, July 2014. Pretoria, South
Africa: NHLS, 2014.
4. Bassili A, Fitzpatrick C, Qadeer E, Fatima R, Floyd K, Jaramillo E. A systematic review of the effective-
ness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. Am J Trop
Med Hyg. 2013; 89. https://doi.org/10.4269/ajtmh.13-0004 PMID: 23926140
5. Floyd K, Hutubessy R, Kliiman K, Centis R, Khurievae N, Jakobowiak W, et al. Cost and cost-effective-
ness of multidrugresistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40:133–42.
https://doi.org/10.1183/09031936.00169411 PMID: 22362862
6. Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I, et al. Costs of inpatient treatment for
multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health. 2013; 8(1):109–16.
7. Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E. Cost per patient of treatment for rifampicin-
resistant tuberculosis in a community-based program in Khayelitsha, South Africa. Trop Med Int Health.
2015; https://doi.org/10.1111/tmi.12544 PMID: 25975868
8. National Institute for Communicable Diseases. South African Tuberculosis Drug Resistance Survey
2012–2014. Johannesburg: National Institute for Communicable Diseases, 2016.
9. Loveday M, Padayatchi N, Wallengren K, Roberts J, Brust JCM, Ngozo J, et al. Association between
Health Systems Performance and Treatment Outcomes in Patients Co-Infected with MDR-TB and HIV
in KwaZulu-Natal, South Africa: Implications for TB Programmes. PLoS ONE. 2014; 9(4):e94016.
https://doi.org/10.1371/journal.pone.0094016 PMID: 24718306
10. Loveday M, Wallengren K, Brust J, Roberts J, Voce A, Margot B, et al. Community-based care vs. cen-
tralised hospitilisation for MDR-TB patients KwaZulu-Natal, South Africa Int J Tuberc Lung Dis. 2015;
19(2):163–71. https://doi.org/10.5588/ijtld.14.0369 PMID: 25574914
11. South African Department of Health. Multi-drug resistant tuberculosis: A policy framework on decentra-
lised and deinstitutionalised managment for South Africa. 2011;Pretoria, South Africa.
12. Wallengren K, Scano F, Margot B, Nunn P, Buthelezi S, Pym A, et al. Drug-Resistant Tuberculosis,
KwaZulu-Natal, South Africa, 2001–2007. EID. 2011; 17(10):1913–6.
13. Day C, Barron P, Massyn N, Padarath A, English R, editors. District Health Barometer 2010/11. Dur-
ban: Health Systems Trust, 2012.
14. Laserson K, Thorpe L, Leimane V, Weyer K, Mitnick C, Riekstina V, et al. Speaking the same language:
treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005; 9
(6):640–5. Epub 2005/06/24. PMID: 15971391.
15. World Health Organisation. Guidelines for the programmatic management of drug-resistant tuber-
culosis. Emergency Update 2008. WHO/HTM/TB/2008.402. Geneva: World Health Organisation,
2008.
16. Bang H, Zhao H. Median-Based Incremental Cost-Effectiveness Ratio (ICER). Journal of statistical the-
ory and practice. 2012; 6(3):428–42. https://doi.org/10.1080/15598608.2012.695571 PubMed PMID:
PMC3577357. PMID: 23441022
17. Department of Public Service and Administration. Salary Scales–Annexure C: Nursing Staff, and
Annexure I. In: National Department of Public Service and Administration, editor. Pretoria, South
Africa2012.
18. KwaZulu-Natal Department of Health. KwaZulu-Natal Financial Reports. Pietermaritzburg, KwaZulu-
Natal2012.
19. StatsSA. Consumer Price Index: Release P0141. Stats South Africa, Pretoria, January 2013 and Janu-
ary 2014.
20. United Nations. UN Operational Rates of Exchange Available: https://treasury.un.org. Accessed March
2015. 2015.
21. Austin P. An introduction to propensity score methods for reducing the effects of confounding in obser-
vational studies. Multivariate Behav Res. 2011; 46(3):399–424. https://doi.org/10.1080/00273171.
2011.568786 PMID: 21818162
22. World Health Organisation. WHO treatment guidelines for drug-resistant tuberculosis 2016 update,
October 2016 revision. WHO/HTM/TB/2016.04. Geneva, Switzerland2016.
Cost-effectiveness of MDR-TB treatment models
PLOS ONE | https://doi.org/10.1371/journal.pone.0196003 April 18, 2018 12 / 13
23. Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M, et al. Community-based treatment
of drug-resistant tuberculosis in Khayelitsha, South Africa Int J Tuberc Lung Dis 2014; 18(4):441–8.
https://doi.org/10.5588/ijtld.13.0742 PMID: 24670700
24. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resis-
tant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17:299–307.
https://doi.org/10.5588/ijtld.12.0537 PMID: 23211716
25. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the Cost of Diagnosis and Management
of Drug Resistant Tuberculosis in South Africa?. PLoS ONE 2013; 8(1):e54587. https://doi.org/10.
1371/journal.pone.0054587 PMID: 23349933
26. Sinanovic E, Ramma L, Vassall A, Azevedo V, Wilkinson L, Ndjeka N, et al. Impact of reduced hospitali-
sation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis
2015; 19:172–8. https://doi.org/10.5588/ijtld.14.0421 PMID: 25574915
27. Bassili A, Fitzpatrick C, Qadeer E, Fatima R, Floyd K, Jaramillo E. Review Article: A Systematic Review
of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant Tuberculo-
sis. American Journal of Tropical Medicine and Hygiene. 2013; 89(2):271–80. https://doi.org/10.4269/
ajtmh.13-0004 PubMed PMID: WOS:000322683100016. PMID: 23926140
28. Lawn, Myer L, Edwards D, Bekker L, Wood R. Short-term and long-term risk of tuberculosis associated
with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009; 23:1717–25. https://
doi.org/10.1097/QAD.0b013e32832d3b6d PMID: 19461502
29. Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, et al. Risk factors for mortality among
MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012; 16(1):90–7.
https://doi.org/10.5588/ijtld.11.0153 PMID: 22236852
30. Ahmed S, Bärnighausen T, Daniels N, Marlink R, Roberts MJ. How providers influence the implementa-
tion of provider-initiated HIV testing and counseling in Botswana: a qualitative study. Implementation
Science. 2016; 11(1):1–13. https://doi.org/10.1186/s13012-015-0361-7 PMID: 26864321
31. Colvin C, Leon N, Wills C, van Niekerk M, Bissell K, Naidoo P. Global-to-local policy transfer in the
introduction of new molecular tuberculosis diagnostics in South Africa. Int J Tuberc Lung Dis 19
(11):1326–38. https://doi.org/10.5588/ijtld.15.0262 PMID: 26467585
32. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB
diagnosis and treatment in South Africa. Social Science & Medicine. 2015; 130:42–50. https://doi.org/
10.1016/j.socscimed.2015.01.046.
33. Loveday M, Sunkari B, Master I, Daftary A, Mehlomakulu V, Hlangu S, et al. Household context and
psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa. The
International Journal of Tuberculosis and Lung Disease. 2018; 22(1):40–6. https://doi.org/10.5588/ijtld.
17.0371 PMID: 29297424
34. Statistics South Africa. Census 2011: Statistical Release P0301.4. STATA Corporation, STATA 13.0:
Pretoria, South Africa, 2013.
35. World Health Organisation. The End TB Strategy: Global strategy and targets for tuberculosis preven-
tion, care and control after 2015. Geneva, Switzerland: World Health Organisation, 2015.
36. Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, et al. Defining Catastrophic Costs
and Comparing Their Importance for Adverse Tuberculosis Outcome with Multi-Drug Resistance: A
Prospective Cohort Study, Peru. PLoS medicine. 2014; 11(7):e1001675. https://doi.org/10.1371/
journal.pmed.1001675 PMID: 25025331
Cost-effectiveness of MDR-TB treatment models
PLOS ONE | https://doi.org/10.1371/journal.pone.0196003 April 18, 2018 13 / 13
